Ilene Ceil Weitz, 2017-04-28T04:46:24+00:00


Back to Index
Ilene Ceil Weitz, MD
Associate Professor of Clinical Medicine
NOR 3461 Health Sciences Campus Los Angeles
+1 323 865 3950


Dr. Ilene C. Weitz is an Associate Professor of Clinical Medicine at the Keck School of Medicine at the University of Southern California (USC). Her practice sites include, LAC+USC Medical Center, Keck Hospital of USC and USC Norris Cancer Hospital. Dr. Weitz is board certified in Internal Medicine and Hematology.

Dr. Weitz earned her medical degree at Medical College of Pennsylvania in Philadelphia, followed by an internship and residency in internal medicine at Cedars-Sinai Medical Center. She conducted a fellowship in hematology/oncology at Scripps Clinic and Research Foundation in La Jolla, California.

Dr. Weitz is a member of the Academy-Simmons College Honor Society, Alpha Omega Alpha, American Medical Womens Association, Los Angeles County Medical Women’s Association, Alumni Associations of Medical College of Pennsylvania and Cedars-Sinai Medical Center, American Society of Hematology, and American Society of Clinical Oncology. She received the Morris Press Humanism Award in 1987 and the “Golden Apple” Outstanding Physician Educator Award in 1990 from Cedars-Sinai Medical Center, as well as the Outstanding Voluntary Faculty Award in the Division of Hematology from USC School of Medicine. Dr Weitz has delivered nationwide lectures and has been published in numerous journals, including American Journal of Clinical Pathology, Hepatology, and Journal of Clinical Oncology, American Journal of Hematology.. She has also contributed eight book chapters or reviews.

Dr. Weitz’ research and clinical interests include hematologic disorders such as anemias, thrombocytopenia and white blood cell disorders, paroxysmal nocgturnal hemoglobinurua (PNH), immune mediated anemias and thrombocytopenia, thrombosis and hemostasis.


Pasadena Magazine: Top Doctor, 2011

Cedars-Sinai Medical Center: Morris Press Humanism Award, 1987

Division of Hematology, Keck School of Medicine: Outstanding Voluntary Faculty, 1996

Cedars-Sinai Medical Center: Golden Apple Outstanding Physician Educator Award, 1990

Simmons College: Academy Honor Society, 1971

Alpha Omega Alpha: Elected Member, 1976


Liebman HA, Weitz IC. Autoimmune Hemolytic Anemia. Med Clin North Am. 2017 Mar; 101(2):351-359. View in: PubMed

Boonyasampant M, Weitz IC, Kay B, Boonchalermvichian C, Liebman HA, Shulman IA. Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab. Transfusion. 2015 Oct; 55(10):2398-403. View in: PubMed

Kelly RJ, Höchsmann B, Szer J, Kulasekararaj A, de Guibert S, Röth A, Weitz IC, Armstrong E, Risitano AM, Patriquin CJ, Terriou L, Muus P, Hill A, Turner MP, Schrezenmeier H, Peffault de Latour R. Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med. 2015 Sep 10; 373(11):1032-9. View in: PubMed

Aldoss I, Mark L, Vrona J, Ramezani L, Weitz I, Mohrbacher AM, Douer D. Adding ascorbic acid to arsenic trioxide produces limited benefit in patients with acute myeloid leukemia excluding acute promyelocytic leukemia. Ann Hematol. 2014 Nov; 93(11):1839-43. View in: PubMed

Raza A, Ravandi F, Rastogi A, Bubis J, Lim SH, Weitz I, Castro-Malaspina H, Galili N, Jawde RA, Illingworth A. A prospective multicenter study of paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure. Cytometry B Clin Cytom. 2014 May; 86(3):175-82. View in: PubMed

Weitz IC. Complement the hemostatic system: an intimate relationship. Thromb Res. 2014 May; 133 Suppl 2:S117-21. View in: PubMed

Weitz IC. Atypical hemolytic uremic syndrome: the role of complement pathway gene mutation analysis. Clin Adv Hematol Oncol. 2014 Apr; 12(4):266-8. View in: PubMed

Chaudhary P, Hepgur M, Sarkissian S, Smith RJ, Weitz IC. Atypical haemolytic-uraemic syndrome due to heterozygous mutations of CFH/CFHR1-3 and complement factor H 479. Blood Transfus. 2014 Jan; 12(1):111-3. View in: PubMed

Raza A, Ravandi F, Rastogi A, Bubis J, Lim SH, Weitz I, Castro-Malaspina H, Galili N, Jawde RA, Illingworth A. A Prospective Multicenter Study of Paroxysmal Nocturnal Hemoglobinuria Cells in Patients with Bone Marrow Failure. Cytometry B Clin Cytom. 2013 Oct 11. View in: PubMed

Szer J, Hill A, Weitz IC. Clinical roundtable monograph: Paroxysmal nocturnal hemoglobinuria: a case-based discussion. Clin Adv Hematol Oncol. 2012 Nov; 10(11 Suppl 21):1-16. View in: PubMed

Weitz IC, Razavi P, Rochanda L, Zwicker J, Furie B, Manly D, Mackman N, Green R, Liebman HA. Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation. Thromb Res. 2012 Sep; 130(3):361-8. View in: PubMed

Weitz I, Sanz MA, Henry D, Schipperus M, Godeau B, Northridge K, Gleeson M, Danese M, Deuson R. A novel approach to the evaluation of bleeding-related episodes in patients with chronic immune thrombocytopenia. Curr Med Res Opin. 2012 May; 28(5):789-96. View in: PubMed

Weitz IC. Thrombosis in patients with paroxysmal nocturnal hemoglobinuria. Semin Thromb Hemost. 2011 Apr; 37(3):315-21. View in: PubMed

Weitz IC. Thrombosis in Paroxysmal Nocturnal Hemoglobinuria - insights into the role of complement in thrombosis. Thromb Res. 2010 Apr; 125 Suppl 2:S106-7. View in: PubMed

Arkfeld DG, Weitz IC. Immune thrombocytopenia in patients with connective tissue disorders and the antiphospholipid antibody syndrome. Hematol Oncol Clin North Am. 2009 Dec; 23(6):1239-49. View in: PubMed

Weitz IC, Liebman HA. The role of oral anticoagulants in tumor biology. Semin Thromb Hemost. 2007 Oct; 33(7):695-8. View in: PubMed

Oliveira B, Arkfeld DG, Weitz IC, Shinada S, Ehresmann G. Successful rituximab therapy of acquired factor VIII inhibitor in a patient with rheumatoid arthritis. J Clin Rheumatol. 2007 Apr; 13(2):89-91. View in: PubMed

Weitz IC. Treatment of immune thrombocytopenia associated with interferon therapy of hepatitis C with the anti-CD20 monoclonal antibody, rituximab. Am J Hematol. 2005 Feb; 78(2):138-41. View in: PubMed

Sutherland DE, Weitz IC, Liebman HA. Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol. 2003 Jan; 72(1):43-52. View in: PubMed

Presant CA, Jacobson J, Wolf W, Waluch V, Weitz IC, Macdonald JS. Does leucovorin alter the intratumoral pharmacokinetics of 5-fluorouracil (5-FU)? A Southwest Oncology Group study. Invest New Drugs. 2002 Nov; 20(4):369-76. View in: PubMed

Weitz IC, Israel VK, Waisman JR, Presant CA, Rochanda L, Liebman HA. Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation. Thromb Haemost. 2002 Aug; 88(2):213-20. View in: PubMed

Powered bySC CTSI